Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study

Fig. 4

CIR, RFS, and OS for patients who were F+/M+, F-/M+, F+/M-, and F-/M- in non-DTA genes after allo-HSCT by tandem assessment (150 patients). (A, B) CIR and NRM by competing risk analysis for F+/M+ (n = 8), F-/M+ (n = 43), F+/M- (n = 6), and F-/M- (n = 93) patients. (C, D) RFS and OS by Kaplan-Meier method for F+/M+ (n = 8), F-/M+ (n = 43), F+/M- (n = 6), and F-/M- (n = 93) patients

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us